Neuronetics, Inc.
NASDAQ:STIMMedical - Diagnostics & Research
+$0.00 today
- Market cap
- $97.16M
- Beta
- 1.04
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.53
Volume 2.55M
Average 2.44M
STIM Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Neuronetics, Inc.NASDAQ: STIM
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $1.36M fell 15.6% year over year, ahead of the -47.4% change in trailing-twelve-month research & development. Sequentially, it fell 18.1% from the prior quarter. Over 3 fiscal years it compounded at -11.0% a year.
Context
- Research & development amounted to 4.4% of revenue in FY2025, down 12.6 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -15.6% holds above the trailing-twelve-month pace of -47.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 6.58M USD
- Year-over-year change
- -48.4%
- 4-year CAGR
- -4.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.58M | -48.4% |
| FY2024 | 2024-12-31 | 12.77M | +34.2% |
| FY2023 | 2023-12-31 | 9.52M | +1.9% |
| FY2022 | 2022-12-31 | 9.34M | +17.8% |
| FY2021 | 2021-12-31 | 7.92M | — |
Research & Development vs competitors
How STIM compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -47.4% is the 8th highest of 9, against a peer median of +5.4%.
- Research & development amounts to 4.2% of revenue for STIM, versus a peer median of 112.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $113.23M USD | +11.4% | -23.3% | 327.7% | |
| LTM Mar 2026 | $85.68M USD | +76.6% | +218.7% | 13864.6% | |
| LTM Mar 2026 | $47.7M USD | -0.5% | -13.2% | 61.1% | |
| LTM Mar 2026 | $46.23M USD | +68.7% | +5.5% | 40.9% | |
| LTM Mar 2026 | $44.75M USD | -15.8% | -0.4% | 154.8% | |
| LTM Mar 2026 | €42.56M EUR | +17.3% | +39.2% | 260.8% | |
| LTM Mar 2026 | $21.15M USD | -1.0% | +12.6% | 112.1% | |
| LTM Mar 2026 | $6.33M USD | -47.4% | -11.0% | 4.2% | |
| LTM Mar 2026 | $4.57M USD | -56.9% | -5.0% | 4.0% | |
ATLNAtlantic International Corp. | LTM Dec 2025 | $0 USD | — | — | 0.0% |
| Peer median (excluding STIM) | — | +5.4% | +2.5% | 112.1% | |
Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.31M | 65.21M | 71.35M | 74.89M | 149.16M |
| Cost of Revenue | 11.65M | 15.48M | 19.64M | 20.73M | 76.85M |
| Gross Profit | 43.66M | 49.72M | 51.71M | 54.16M | 72.31M |
| Gross Margin | 78.9% | 76.3% | 72.5% | 72.3% | 48.5% |
| Research & Development | 7.92M | 9.34M | 9.52M | 12.77M | 6.58M |
| Selling, General & Admin | 63.3M | 75.5M | 72.74M | 75.95M | 97.16M |
| Operating Expenses | 71.22M | 84.83M | 82.26M | 88.72M | 103.74M |
| Depreciation & Amortization | 1.06M | 1.65M | 2.01M | 2.07M | 3.47M |
| EBITDA | (26.81M) | (31.96M) | (22.76M) | (34.37M) | (27.12M) |
| EBITDA Margin | -48.5% | -49.0% | -31.9% | -45.9% | -18.2% |
| Operating Income | (27.56M) | (35.11M) | (30.55M) | (34.56M) | (31.44M) |
| Operating Margin | -49.8% | -53.8% | -42.8% | -46.2% | -21.1% |
| Interest Income | 0 | 0 | 24K | 0 | 0 |
| Interest Expense | 3.3M | 3.6M | 5.42M | 7.29M | 8.42M |
| Other Income / Expenses | (3.61M) | (2.1M) | 365K | (9.18M) | (7.56M) |
| Income Before Tax | (31.17M) | (37.21M) | (30.19M) | (43.74M) | (39M) |
| Pre-Tax Margin | -56.4% | -57.1% | -42.3% | -58.4% | -26.1% |
| Income Tax Expense | 0 | 0 | (24K) | (14K) | 0 |
| Net Income | (31.19M) | (37.16M) | (30.19M) | (43.71M) | (39M) |
| Net Margin | -56.4% | -57.0% | -42.3% | -58.4% | -26.1% |
| EPS (Basic) | (1.22) | (1.38) | (1.05) | (1.38) | (0.59) |
| EPS (Diluted) | (1.22) | (1.38) | (1.05) | (1.38) | (0.59) |
| Weighted Avg Shares | 25.48M | 26.9M | 28.66M | 31.73M | 65.95M |
| Weighted Avg Shares (Diluted) | 25.48M | 26.9M | 28.66M | 31.73M | 65.95M |
Neuronetics, Inc.
NASDAQ:STIM
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.